Brean Capital analyst Jason Wittes penned a glowing report on LDR, expecting growth in the future, according to a Benzinga report.
Here are five quick updates:
• Brean Capital gave LDR a "buy"
• One-year target price was set at $50
• LDR has differentiated products, boosting potential
• JMP Securities maintains its "market outperform"
• Piper Jaffray initiated coverage in January at "overweight
"Given the degree of differentiation and the potential for LDRH's cervical disc technology to disrupt the current cervical fusion market, we think this is a unique company with a significantly better growth profile than its small- to mid-cap peers," according to Mr. Wittes.
LDR has both cervical disc replacement and fusion technologies. The company's Mobi-C disc is the only cervical disc with FDA clearance for two-level disc replacement procedures.